Orthocell Bolsters Cash to $49.6M Following $3M R&D Tax Refund
Orthocell Limited has secured a $3 million R&D tax incentive refund, elevating its total cash reserves to $49.6 million. This non-dilutive capital injection strengthens the regenerative medicine company's balance sheet as it scales the global commercialization of its nerve and tissue repair products.